Regulatory Pfizer’s Hympavzi secures FDA expanded indications for haemophilia Pharmaceutical TechnologyPfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B.HematologyRead full story pharminent June 9, 2026 (Last updated: June 9, 2026) Pharmaceutical Technology Pfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B. Hematology Read full story Post navigation Previous: J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1BNext: ADA: AZ reveals oral GLP-1 data in obesity, diabetes Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
